A Phase 1a/1b Study of a Novel Anti-PD-L1 Checkpoint Antibody (LY3300054) Administered Alone or in Combination With Other Agents in Advanced Refractory Solid Tumors (Phase 1a/1b Anti-PD-L1 Combinations in Tumors-PACT)

Trial Profile

A Phase 1a/1b Study of a Novel Anti-PD-L1 Checkpoint Antibody (LY3300054) Administered Alone or in Combination With Other Agents in Advanced Refractory Solid Tumors (Phase 1a/1b Anti-PD-L1 Combinations in Tumors-PACT)

Recruiting
Phase of Trial: Phase I

Latest Information Update: 10 Oct 2017

At a glance

  • Drugs LY 3300054 (Primary) ; Necitumumab (Primary) ; Ramucirumab (Primary)
  • Indications Solid tumours
  • Focus Adverse reactions
  • Acronyms PACT
  • Sponsors Eli Lilly
  • Most Recent Events

    • 05 Oct 2017 Planned End Date changed from 6 Jul 2018 to 1 Jul 2019.
    • 05 Oct 2017 Planned primary completion date changed from 6 Jul 2018 to 1 Jul 2019.
    • 07 Apr 2017 Planned number of patients changed from 205 to 100.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top